Lumira Ventures

Lumira Ventures is a venture capital firm that specializes in investing in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007 and headquartered in Toronto, Ontario, it has additional offices in Montreal, Vancouver, and Boston. The firm focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies, primarily in North America, particularly Canada and the United States. Lumira Ventures typically invests between 5 million and 15 million in its portfolio companies, which currently includes over 30 active investees. The firm collaborates closely with management teams to enhance the value of their technology pipelines through strategic financing, board participation, and facilitating access to funding sources, partners, and market opportunities. With a history of over 100 investments since 1989, Lumira Ventures is recognized for its commitment to fostering innovation and addressing significant unmet needs in healthcare.

Gerry Brunk, MBA

Managing Director

Daniel Hetu

Managing Director

Jacki Jenuth

Partner

Vasco Larcina. CPA

CFO

Alice Luo

Analyst

David Novak

Venture Partner

Suman Rao

Senior Associate

Benjamin Rovinski, Ph.D.

Managing Director

Nikhil Thatte

Principal

Peter van der Velden, MBA, M.Sc.

Managing General Partner

Benjamin Rovinski Ph.D

Managing Director

Baye Galligan, M.A., HBA

Associate

Past deals in British Columbia

Zymeworks

Series A in 2016
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics primarily for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various cancers such as biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials targeting advanced or metastatic HER2-expressing cancers. Zymeworks utilizes a combination of proprietary molecular modeling, simulation software, and high-performance computing to optimize therapeutic antibodies and other protein-based treatments. The company has established strategic partnerships with several leading pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Additionally, Zymeworks is advancing a preclinical pipeline that includes candidates for oncology and other therapeutic areas, reflecting its commitment to addressing unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.